| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
TMEPAI is a transmembrane protein which is highly expressed in many types of cancer. The knock-out of TMEPAI in breast cancer cells shows less tumorigenic and lung metastatic abilities, thus TMEPAI potentiates oncogenic properties in cancer cells. Additionally we found that the tumors obtained from TMEPAI knock-out cells reduced the expression of VEGF and IL-8 that are well-known proangiogenic factors.
Moreover, we revealed that TMEPAI is involved in resistance for anti-tumor drugs in triple negative breast cancer cells and the PY motifs in intracellular region of TMEPAI are responsible for the regulation of Wnt signaling pathway. We screened TMEPAI binding macrocyclic peptide and obtained several high affinity binders. Hence we try to apply these macrocyclic peptides for clinical usage.
|
